Syquant Capital Sas Bio N Tech Se Call Options Transaction History
Syquant Capital Sas
- $302 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BNTX
# of Institutions
317Shares Held
40.8MCall Options Held
1.37MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$859 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$452 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$428 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$385 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$203 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.9B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...